Emma Reeve sold $934k of PTCT
director at PTC THERAPEUTICS, INC.. 15,705 shares at an average of $59.50, traded Sep 11, 2025, filed Sep 16, 2025.
Score components
- +15RoleDirector
- +24Trade size$934k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001680329-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2025 | SOpen-market sale Common Stock10b5-1 | -3,534 | $59.50 | $210k | 11,666 | Sep 16, 2025 |
| Sep 11, 2025 | SOpen-market sale Common Stock10b5-1 | -1,334 | $59.50 | $79k | 10,332 | Sep 16, 2025 |
| Sep 11, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $25.69 | $257k | 20,332 | Sep 16, 2025 |
| Sep 11, 2025 | SOpen-market sale Common Stock10b5-1 | -10,000 | $59.50 | $595k | 10,332 | Sep 16, 2025 |
| Sep 11, 2025 | MOption exercise Common Stock10b5-1 | +837 | $33.63 | $28k | 11,169 | Sep 16, 2025 |
| Sep 11, 2025 | SOpen-market sale Common Stock10b5-1 | -837 | $59.50 | $50k | 10,332 | Sep 16, 2025 |
| Sep 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Sep 16, 2025 |
| Sep 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -837 | $0.00 | $0 | 0 | Sep 16, 2025 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 14Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $693k 8,130 shares | -13% | |
| 23Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $2.3M 26,283 shares | -43% | |
| 23Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $1.9M 23,749 shares | -28% | |
| 11Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $823k 10,462 shares | -9% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $203k 2,812 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.